DDInter458 DDInter1544
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Cyclosporine {u} (Compound) treats {v} (Disease) focal segmental glomerulosclerosis
Cyclosporine {u} (Compound) binds {v} (Gene) SLC10A2
Cyclosporine {u} (Compound) upregulates {v} (Gene) IFRD1
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Cyclosporine {u} (Compound) downregulates {v} (Gene) CENPF
Cyclosporine {u} (Compound) causes {v} (Side Effect) Injury
Cyclosporine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPIB
Cyclosporine (Compound) treats focal segmental glomerulosclerosis (Disease)
Cyclosporine (Compound) binds SLC10A2 (Gene)
Cyclosporine (Compound) upregulates IFRD1 (Gene)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Cyclosporine (Compound) downregulates CENPF (Gene)
Cyclosporine (Compound) causes Injury (Side Effect)
Cyclosporine (Compound) binds PPIB (Gene) and Cyclosporine (Compound) upregulates PPIB (Gene)